GT Biopharma Reports Third Quarter 2018 Financial Results and Provides Business Update – Recent corporate, preclinical, clinical and regulatory advancements expected to position Company for a transformational 2019 – – FDA clearance of IND to advance first-in-class TriKE, GTB-3550, into...

GT Biopharma Receives FDA Clearance to Commence First-in-Human Phase 1 Study of its First-in-Class Tri-Specific Killer Engager (TriKE), GTB-3550, for the Treatment of Acute Myelogenous Leukemia, Myelodysplatic Syndrome and Mastocytosis LOS ANGELES, Nov. 01, 2018 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (OTCQB: GTBP and Euronext Paris GTBP.PA) ("GT Biopharma" or the "Company"), an immuno-oncology biotechnology company focused on...

GT Biopharma, Inc. Files Application for NASDAQ Capital Market Listing WASHINGTON, Dec. 18, 2017 (GLOBE NEWSWIRE) -- GT Biopharma Inc. (OTCQB:GTBP) today announced that the Company has filed an application to list its common stock on the NASDAQ Capital Market. GT...